The Essure birth control procedure, approved in the United States in 2002, is an allegedly permanent, but less invasive means of surgical sterilization. With the Essure product, marketed by Bayer AG’s affiliate Conceptus, Inc., a woman has a coil inserted into each fallopian tube, blocking the tubes and preventing conception.
The U.S. Food and Drug Administration (FDA), though, has received more than 5,000 complaints linked to the Essure insert, with users reporting a lengthy list of side effects, including seven deaths. Among the adverse health consequences acknowledged by the FDA are:
- Punctures or perforations in the uterine wall caused by the insert
- Failure of the device, leading to unwanted pregnancy
- Changes in menstrual cycles
- Nausea, vomiting, cramping and vaginal bleeding
- Allergic reactions to materials in the insert
- Weight gain
- Hair loss
- Anxiety or depression
After recent complaints to the FDA, federal investigators have determined that Bayer actively concealed information from the FDA during the product’s approval process, and engaged in other negligence, including using substandard materials when manufacturing the product. Mass tort litigation has been filed naming Bayer and Conceptus as defendants.
If you or someone you love has suffered injury using the Essure birth control product, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
I often am asked by clients how they can avoid probate. In some situations, it is appropriate to tak…Read More 12 Jul 2019, Friday
What is the Hatch Act and How Did Kellyanne Conway Violate It?
Office of Special Counsel Calls White House Counselor a “Repeat Offender” and Calls for…Read More 25 Jun 2019, Tuesday
TEVA Pharmaceutical Settles Opioid Lawsuit Before Trial
Israeli Drug Company Agrees to Pay $85 Million A second major pharmaceutical company has decided to…Read More 28 May 2019, Tuesday